2024-515895-11-00招募中4 期
Determination Of Molecular Status And Benefit Of Use Fludeoxyglucose (18F-FDG) In PET/CT imagining In Juvenile Patients With Histiocytosis
Instytut Matki I Dziecka1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2024年8月26日最近更新:
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- EFS – (event-free survival).
研究概览
简要总结
Determination of molecular status and benefit and safety of use fludeoxyglucose (18-FDG) in PET/CT imagening in juvenile patients with histiocytosis.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 是
入选标准
- •Patient under 18 years of age at the time of inclusion.
- •Histopatologically confirmed or suspected histiocytosis (based on prior test results).
- •Signing of informed consent for trial participation according with current legal regulations.
排除标准
- •Lack of inclusion criteria.
- •Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial.
结局指标
主要结局
EFS – (event-free survival).
EFS – (event-free survival).
次要结局
- PFS (Progression-Free Survival)
- OS (Overall Survival)
- ORR (Overall Response Rate)
- Reactivation rate after 2 years
- Rate of participants presenting with Adverse Events separated by degree of intensity, category, affected organ or system.
研究者
Klinika Onkologii i Chirurgii Onkologicznej Dzieci i Młodzieży IMID
Scientific
Instytut Matki I Dziecka
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Personalized cancer therapy for CancerCTRI/2018/02/011808Datar Cancer Genetics Limited209
尚未招募
不适用
The molecular biologic chracteristic analysis of primary fallopian tube carcinoma.primary fallopian tube carcinomaJPRN-UMIN000020255Department of Gynecology and Obstetrics , Tohoku University60
招募中
2 期
Prospective Evaluation of the Molecular Effects of Itraconazoleas an anti-cancer agent: A Window of Opportunity Studysolid tumorsJPRN-UMIN000018388Hyogo College of Medicine20
招募中
2 期
Window trialJPRN-jRCTs051190006Tsubamoto Hiroshi200
尚未招募
不适用
iver protective drug action of homoeopathic preparation of Myrica cerifera 3C on Non alcoholic fatty liver diseaseCTRI/2022/02/040009Dr Raja Manoharan